SCHEMBL7016502

SCHEMBL7016502

COc1cccc(C[S+]([O-])c2nc3ccccc3[nH]2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.60
RAB9A P51151 8/20 0.60
NPC1 O15118 7/20 0.60
TP53 P04637 3/20 0.60
LMNA P02545 1/20 0.60
ALDH1A1 P00352 4/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HTT P42858 2/20 0.52
CYP2E1 P05181 3/20 0.46
CYP2C8 P10632 3/20 0.46
CYP2D6 P10635 3/20 0.46
CYP2C9 P11712 3/20 0.46
CYP2B6 P20813 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
PKM P14618 3/20 0.45
DRD4 P21917 1/20 0.44
MAPK10 P53779 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7012212 0.86 NPC1 (0.52) SMN1; SMN2RAB9ANPC1TP53LMNA
SCHEMBL9843061 0.86 NPC1 (0.52) SMN1; SMN2RAB9ANPC1TP53LMNA
SCHEMBL7012214 0.86 RAB9A (0.63) SMN1; SMN2RAB9ANPC1TP53LMNA
SCHEMBL9692820 0.86 NPC1 (0.52) SMN1; SMN2RAB9ANPC1TP53LMNA
SCHEMBL9507972 0.84 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANPC1TP53LMNA
SCHEMBL7015735 0.82 EGFR (0.48) SMN1; SMN2RAB9ANPC1TP53LMNA
SCHEMBL7015738 0.82 MAPT (0.52) SMN1; SMN2RAB9ANPC1LMNAALDH1A1
SCHEMBL636639 0.81 GAA (0.50) SMN1; SMN2RAB9ANPC1TP53ALDH1A1
SCHEMBL6483278 0.81 MAPT (0.55) SMN1; SMN2RAB9ANPC1TP53LMNA
SCHEMBL6475028 0.80 ATP4A (0.57) SMN1; SMN2RAB9ANPC1TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US disclosed
EP-1105387-B1 PRODRUGS OF PROTON PUMP INHIBITORS WINSTON PHARMATEUTICALS LLC (US) 2003-01-29 EP disclosed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 WO disclosed